Basic, Laboratory and Clinical Aspects of Venous and Arterial Thromboembolic Diseases
|
|
|
- Gwendoline Brown
- 8 years ago
- Views:
Transcription
1 HSR Istituto Scientifico HS Raffaele Milano I.R.C.C.S. Policlinico S. Matteo Pavia 8 th International Winter Meeting on Coagulation Basic, Laboratory and Clinical Aspects of Venous and Arterial Thromboembolic Diseases Bormio (SO) - (Italy) April 6-12, 2008 With the auspices of: SIBioC (Società Italiana di Biochimica clinica e Biologia Molecolare clinica) SISET (Società Italiana per lo Studio dell Emostasi e della Trombosi) C.M.E. Accreditation PROGRAM
2 SCIENTIFIC COMMITTEE Marco Cattaneo (Milano, Italy)
3 SPEAKERS AND CHAIRMEN SPEAKERS AND CHAIRMEN Walter Ageno (Varese, Italy) Giancarlo Agnelli (Perugia, Italy) Ugo Armani (Genova, Italy) Alessandra Balduini (Pavia, Italy) Giovanni Barosi (Pavia, Italy) Francesco Bernardi (Ferrara, Italy) Cristina Berteanu (Bucharest, Romania) Benjamin Brenner (Haifa, Israel) Harry Büller (Amsterdam, The Netherlands) Marco Cattaneo (Milano, Italy) Andreas Calatzis (Munich, Germany) Marina Camera (Milano, Italy) Nicola Ciavarella (Bari, Italy) Mario Colucci (Bari, Italy) Antonio Coppola (Napoli, Italy) Filippo Crea (Roma, Italy) Björn Dahlbäck (Malmö, Sweden) Bruce Davidson (Doha, Qatar) Giovanni de Gaetano (Campobasso, Italy) Andrea De Gasperi (Milano, Italy) Luigi De Marco (Aviano, Italy) Maria Benedetta Donati (Campobasso, Italy) Bengt Eriksson (Göteborg, Sweden) Anna Falanga (Bergamo, Italy) Luciano Gattinoni (Milano, Italy) Alfonso Iorio (Perugia, Italy) Michael Lassen (Copenhagen, Denmark) Ton Lensing (Amsterdam, The Netherlands) Maddalena Lettino (Pavia, Italy) Kurt Mahan (Albuquerque, USA) Marina Marchetti (Bergamo, Italy) Norma Maugeri (Milano, Italy) Mario Mazzucato (Aviano, Italy) Jim Morrissey (Urbana, USA) Gualtiero Palareti (Bologna, Italy) Vittorio Pengo (Padova, Italy) Flora Peyvandi (Milano, Italy) Quirino Piacevoli (Roma, Italy) Mario Pini (Fidenza, Italy) Paolo Prandoni (Padova, Italy) Domenico Prisco (Firenze, Italy) Alireza Rezaie (St. Louis, USA) Elena Santagostino (Milano, Italy) Mario Schiavoni (Scorrano-Lecce, Italy) Paolo Simioni (Padova, Italy) Alex Spyropoulos (Albuquerque, USA) A. Graham Turpie (Hamilton, Canada) Francesco Violi (Roma, Italy)
4 PROGRAM PROGRAM Sunday, April p.m. Welcome cocktail 7.00 p.m. Opening of the Meeting Monday, April 7 PRIMARY HEMOSTASIS Chairmen: Marco Cattaneo (Milano, Italy) Maria Benedetta Donati (Campobasso, Italy) Calcium signaling modulates platelet activation and thrombus formation under flow Luigi De Marco (Aviano, Italy) Mario Mazzucato (Aviano, Italy) From megakaryocytes to platelets: regulation, environment and pathology Alessandra Balduini (Pavia, Italy) Aspirin resistance in the meta-analysis era Giovanni de Gaetano (Campobasso, Italy) New anti-platelet agents inhibiting the P2Y12 receptors Marco Cattaneo (Milano, Italy) PROPHYLAXIS AND TREATMENT OF THROMBOEMBOLISM - I Chairmen: Michael Lassen (Copenhagen, Denmark) Thrombophilia and pregnancy complications Benjamin Brenner (Haifa, Israel) Thrombosis in hematological malignancies Anna Falanga (Bergamo, Italy) Indirect factor Xa inhibitors in acute coronary syndromes Maddalena Lettino (Pavia, Italy) Tuesday, April 8 NEW HEMOSTASIS TESTS Chairmen: Ugo Armani (Genova, Italy) Nicola Ciavarella (Bari, Italy) Evaluation of the overall coagulation potential by the thrombin generation assay Marina Marchetti (Bergamo, Italy) New Rotation Thromboelastography (ROTEM) in thrombotic and haemorrhagic disorders: lights and shadows Paolo Simioni (Padova, Italy) Assessment of Aspirin and Clopidogrel action in whole blood using the multiplate analyzer Andreas Calatzis (Munich, Germany) PiCT: a new universal assay for heparin, LMWH, and direct Fxa/FIIa antagonists Andreas Calatzis (Munich, Germany) SEVERE SEPSIS Chairmen: Mario Colucci (Bari, Italy) Björn Dahlbäck (Malmö, Sweden) The protein C pathway at the interface of coagulation and inflammation Activated protein C in sepsis: the clinical evidence Luciano Gattinoni (Milano, Italy) The ligand occupancy of EPCR switches the PAR-1-dependent signalling specificity of thrombin Alireza Rezaie (St. Louis, USA) Zymogen protein C in severe sepsis: the clinical evidence Quirino Piacevoli (Roma, Italy) Enzyme and/or zymogen? Venous thrombosis in the elderly Cristina Berteanu (Bucharest, Romania)
5 PROGRAM PROGRAM Wednesday, April 9 PROPHYLAXIS AND TREATMENT OF THROMBOEMBOLISM - II Chairmen: Mario Pini (Fidenza, Italy) Domenico Prisco (Firenze, Italy) Homocysteine: still a relevant thrombophilia marker? Walter Ageno (Varese, Italy) D-dimer course and VTE recurrence during 12 months after anticoagulation withdrawal; results of the PROLONG II study Gualtiero Palareti (Bologna, Italy) Recurrent VTE and bleeding in relation to warfarin, acenocoumarol and phenprocoumon for the treatment of VTE Ton Lensing (Amsterdam, The Netherlands) New anticoagulants in atrial fibrillation Vittorio Pengo (Padova, Italy) Improving safety in clinical studies of antithrombotics Bruce Davidson (Doha, Qatar) ARTERIAL THROMBOSIS Chairmen: Walter Ageno (Varese, Italy) Giovanni de Gaetano (Campobasso, Italy) Atherothrombosis, Tissue factor and platelets: an update Marina Camera (Milano, Italy) Oxidative stress and atherogenesis Francesco Violi (Roma, Italy) Lymphocyte activation and coronary instability Filippo Crea (Roma, Italy) Thursday, April a.m. Morning Session MECHANISMS IN HEMOSTASIS AND THROMBOSIS- I Chairmen: Jim Morrissey (Urbana, USA) Effects of prothrombin, factor Xa and protein S on the individual activated protein C-mediated cleavages of coagulation factor Va Björn Dahlbäck (Malmö, Sweden) Diabetes and inflammatory bowel disease as potential targets for protein C therapy The cross-talk between coagulation and fibrinolysis. The role of cells Mario Colucci (Bari, Italy) PROPHYLAXIS AND TREATMENT OF THROMBOEMBOLISM - III Chairmen: Giancarlo Agnelli (Perugia, Italy) A. Graham Turpie (Hamilton, Canada) The Dabigatran program Bengt Eriksson (Göteborg, Sweden) The Rivaroxaban program The Apixaban program Michael Lassen (Copenhagen, Denmark) The YM-150 program Giancarlo Agnelli (Perugia, Italy) The Idraparinux program Harry Büller (Amsterdam, The Netherlands) Early simultaneous activation and cross-talk of platelets and leukocytes in acute myocardial infarction Norma Maugeri (Milano, Italy) Venous and arterial thrombosis: is there a link? Paolo Prandoni (Padova, Italy)
6 PROGRAM PROGRAM Friday, April 11 Saturday, April 12 MECHANISMS IN HEMOSTASIS AND THROMBOSIS - II Chairmen: Marco Cattaneo (Milano, Italy) Blood Clotting on Membrane Nanodomains Jim Morrissey (Urbana, USA) Gas6 and protein S, vitamin K-dependent ligands for the Axl-family of receptor tyrosine kinases Björn Dahlbäck (Malmö, Sweden) JAK-2 in idiopathic splancnic thrombosis Giovanni Barosi (Pavia, Italy) Polyphosphate Modulates Clot Structure Jim Morrissey (Urbana, USA) Oral anticoagulant therapy: a look to the future A. Graham Turpie (Hamilton, Canada) BLEEDING DISORDERS Chairmen: Alfonso Iorio (Perugia, Italy) Mario Schiavoni (Scorrano-Lecce, Italy) Surgery at high risk of bleeding Andrea De Gasperi (Milano, Italy) MANAGEMENT OF ANTITHROMBOTIC PROPHYLAXIS AND TREATMENT Chairmen: Thrombosis in children Paolo Simioni (Padova, Italy) The IMPROVE registry Mario Pini (Fidenza, Italy) Bridging in anticoagulation Alex Spyropoulos (Albuquerque, USA) How a pharmacy-driven, physician-championed program can improve rates of appropriate VTE prophylaxis in a hospital Kurt Mahan (Albuquerque, USA) Anti-platelet agents in coronary stenting Domenico Prisco (Firenze, Italy) CONCLUSIVE REMARKS Rare bleeding disorders Flora Peyvandi (Milano, Italy) Molecular genetics and biology of hemorrhagic diseases Francesco Bernardi (Ferrara, Italy) Treatment of hemophiliacs with inhibitors Elena Santagostino (Milano, Italy) The PROFIT Study Antonio Coppola (Napoli, Italy)
7 SCIENTIFIC INFORMATION GENERAL INFORMATION PROJECTIONS PC Power Point projection will be available. Pen drives or CDs must be handed in at the Projection center at least 30 minutes before the beginning of the session. OFFICIAL LANGUAGE The official language of the meeting is English. No simultaneous translation will be provided. CONTINUING MEDICAL EDUCATION This Meeting has applied for the Italian Health Ministry Accreditation. CONGRESS VENUE PALACE HOTEL BORMIO Via Milano, BORMIO (SO) ph fax ORGANIZING SECRETARIAT NL Congressi s.r.l. Via di Filomarino, Roma Ph Fax REGISTRATION FEE Euro 420 (VAT 20% included) The registration fee includes: Congress documents Coffee Breaks Abstract Book Certificate of Attendance C.M.E. Certificate
8 ACKNOWLEDGEMENTS The Scientific Committee would like to thank
Friday April 8 th 2016
Preliminary Scientific Program - ICTHIC April 8-10, 2016 Friday April 8 th 2016 9,00-11,00 am Industry sponsored session 11,00-11,15 am Congress Opening: A Falanga, FR Rickles, B Brenner 11,15-1,30 pm
Centro CARDIOLOGICO Monzino - IRCCS
XIV ISA Satellite Symposium Milan June 16-17, 2006 Novel Insights in Atherothrombosis: from Pathophysiology to Therapy Centro CARDIOLOGICO Monzino - IRCCS Research for care Scientific Director: Paolo Biglioli
MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants
MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013 Anticoagulants Anticoagulants are agents that prevent the formation of blood clots. Before we can talk about
International Workshop ANTITHROMBOTIC THERAPY IN ACUTE CORONARY SYNDROMES. Villa Olmo - Como
International Workshop ANTITHROMBOTIC THERAPY IN ACUTE CORONARY SYNDROMES Villa Olmo - Como 24-25 February 2012 Scientific Secretary Diego Ardissino, M.D. Unità Operativa di Cardiologia Dipartimento Assistenziale
New anticoagulants: Monitoring or not Monitoring? Not Monitoring
The 2 nd World Congress on CONTROVERSIES IN HEMATOLOGY (COHEM) Barcelona, Spain September 6 8, 2012 New anticoagulants: Monitoring or not Monitoring? Not Monitoring Anna Falanga, MD Immunohematology and
Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban
New Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
What Does Pregnancy Have to Do With Blood Clots in a Woman s Legs?
Patient s Guide to Prevention of Blood Clots During Pregnancy: Use of Blood-Thinning A Patient s Guide to Prevention of Blood Clots During Pregnancy: Use of Blood-Thinning Drugs to Prevent Abnormal Blood
ABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
Medication Policy Manual. Topic: Eliquis, apixaban Date of Origin: July 12, 2013. Committee Approval Date: July 11, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru313 Topic: Eliquis, apixaban Date of Origin: July 12, 2013 Committee Approval Date: July 11, 2014 Next Review Date: July 2015 Effective Date: August 1, 2014 IMPORTANT
Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:
Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
East Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
DVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors
News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients
Thrombophilia. Steven R. Lentz, M.D. Ph.D. Carver College of Medicine The University of Iowa May 2003
Thrombophilia Steven R. Lentz, M.D. Ph.D. Carver College of Medicine The University of Iowa May 2003 Thrombophilia Hereditary and acquired risk factors for thrombosis Venous thromboembolism Arterial thromboembolism
THE BENEFITS OF RIVAROXABAN (XARELTO ) ACROSS MULTIPLE INDICATIONS AND THE RELEVANCE TO CARDIOLOGISTS
THE BENEFITS OF RIVAROXABAN (XARELTO ) ACROSS MULTIPLE INDICATIONS AND THE RELEVANCE TO CARDIOLOGISTS Ingo Ahrens, Christoph Bode Cardiology and Angiology I, Heart Center Freiburg University, Freiburg,
Comparison between New Oral Anticoagulants and Warfarin
Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several
The Anticoagulated Patient A Hematologist s Perspective
The Anticoagulated Patient A Hematologist s Perspective Deborah M. Siegal MD MSc FRCPC Clinical Scholar Division of Hematology and Thromboembolism Thrombosis Canada Research Fellow McMaster University
Thrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs
A Patient s Guide to Primary and Secondary Prevention of PATIENT EDUCATION GUIDE What Is Cardiovascular Disease? Cardiovascular disease (CVD) is a broad term that covers any disease of the heart and circulatory
Investor News. Not intended for U.S. and UK media
Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in
The new oral anticoagulants & the future of haemostasis laboratory testing. Alcohol: the good, the bad and the ugly
The new oral anticoagulants & the future of haemostasis laboratory testing Emmanuel J Favaloro Diagnostic Haemostasis Laboratory, Institute of Clinical Pathology & Medical Research, ICPMR, Pathology West,
Disclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU
New Agents for Treatment of DVT Disclosure PI Adopt and Amplify trials Mark Oliver, MD, RVT, RPVI,FSVU BMS and Pfizer Speaker VTE Venous Thromboembolism Recognized DVT s New : 170,000 Recurrent : 90,000
Venous Thromboembolic Treatment Guidelines
Venous Thromboembolic Treatment Guidelines About the NYU Venous Thromboembolic Center (VTEC) The center s mission is to deliver advanced screening, detection, care, and management services for patients
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment
The Anti coagulated Patient: The Cardiologist s View. February 28, 2015
The Anti coagulated Patient: The Cardiologist s View February 28, 2015 Conflicts Dr. McMurtry has no conflicts to disclose. CanMeds Medical Expert (as Medical Experts, physicians integrate all of the CanMEDS
Thrombosis and Bleeding
Many questions, few answers Thrombosis and Bleeding Pierre Noel MD Mayo Arizona Scope of the Problem Thrombosis PV 12-39% ET 11-25% MF 10% 60-70% of thrombosis are arterial Splanchnic and cerebral thrombosis
The novel anticoagulants: entering a new era
Review article Peer reviewed article SWISS MED WKLY 2009;139(5 6):60 64 www.smw.ch 60 The novel anticoagulants: entering a new era Henri Bounameaux Division of Angiology and Haemostasis, Department of
Lupus anticoagulant Pocket card
Lupus anticoagulant Pocket card Issue number 5 2012 Antiphospholipid Syndrome 1 The antiphospholipid syndrome (APS) is diagnosed in patients with recurrent thromboembolic events and /or pregnancy loss
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
Hot Line Session at European Society of Cardiology (ESC) Congress 2014:
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Once-Daily
Disclosures. Overview. Anticoagulation in 2015: Where We Are and Where We Are Going. Impact of NOACs in Canada
Anticoagulation in 2015: Where We Are and Where We Are Going Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke
New Anticoagulants: What to Use What to Avoid
New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA
Optimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015
Optimizing Anticoagulation Selection for Your Patient C. Andrew Brian MD, FACC NCVH 2015 Who Needs to Be Anticoagulated and What is the Patient s Risk? 1. Atrial Fibrillation ( nonvalvular ) 2. What regimen
Committee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
The author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
6/19/2012. Update on Venous Thromboembolism Prophylaxis. Disclosure. Learning Objectives. No conflicts of interest to declare
Update on Venous Thromboembolism Prophylaxis Disclosure No conflicts of interest to declare Learning Objectives After completion of this presentation, participants should be able to: Define venous thromboembolism,
Time of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast
WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION Van Crisco, MD, FACC, FSCAI First Coast Conflicts of Interest I have been a paid consultant and speaker for AstraZeneca, makers of
Anticoagulant therapy
Anticoagulation: The risks Anticoagulant therapy 1990 2002: 600 incidents reported 120 resulted in death of patient 92 deaths related to warfarin usage 28 reports related to heparin usage Incidents in
2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS
ANTICOAGULATION UPDATE C AR R I E P AL M E R, D N P, RN, AN P - BC OBJECTIVES At the end of the presentation, the NP will be able to: Identify new indications for target-specific oral anticoagulants (TSOACs),
FOCUS ON BIOLOGICAL THERAPIES IN HEMATOLOGIC MALIGNANCIES
FOCUS ON BIOLOGICAL THERAPIES IN HEMATOLOGIC MALIGNANCIES Siena, November 4-5, 2004 AUSPICES SIE SIES University of Siena Department of Medicine and Immunological Sciences Section of Hematology and Transplantion,
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET Departments of Gastroenterology and Hepatology,
USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN)
USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals:
NHS FIFE WIDE POLICY - HAEMATOLOGY MANAGEMENT OF ANTICOAGULATION THERAPY DURING MAJOR AND MINOR ELECTIVE SURGERY
MANAGEMENT OF ANTICOAGULATION THERAPY DURING MAJOR AND MINOR ELECTIVE SURGERY The scope of this guideline is to simplify the management of patients on oral anticoagulation undergoing major and minor surgery.
Vittorio Pengo M.D. (CV as of April 2014)
Vittorio Pengo M.D. (CV as of April 2014) Professor of Cardiovascular Medicine, Department of Cardiac Thoracic and Vascular Sciences, and Director of Thrombosis Center, University of Padova School of Medicine,
Top 10 Thrombosis and Anticoagulation Highlights from ASH 2014
Top 10 Thrombosis and Anticoagulation Highlights from ASH 2014 Stephan Moll, MD UNC School of Medicine, Chapel Hill, NC 1. New Anticoagulant Factor XI lowering drug NEJM publication Dec 7 th (late- breaking
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS AND PHYSICIANS TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVES: To provide a comparison of the new
Clinical Practice Guideline for Anticoagulation Management
Clinical Practice Guideline for Anticoagulation Management This guideline is to inform practitioners of the Standard of Care for providing safe and effective anticoagulation management for ambulatory patients.
3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
STROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
Critical Bleeding Reversal Protocol
Critical Bleeding Reversal Protocol Coagulopathy, either drug related or multifactorial, is a major contributing factor to bleeding related mortality in a variety of clinical settings. Standard therapy
Hot Topics: Current PFO Recommendations and Loop Monitoring/Cryptogenic Stroke.
Hot Topics: Current PFO Recommendations and Loop Monitoring/Cryptogenic Stroke. Favoriteplus.com www.heartrhythmcharity.org.uk www.forbes.com Victor J. Mazza, MD Assistant Professor of Medicine Cardiology,
Analytical Specifications RIVAROXABAN
Page 1 of 9 ANALYTE NAME AND STRUCTURE - RIVAROXABAN SYNONYMS Xarelto CATEGORY Anticoagulant TEST CODE PURPOSE Therapeutic Drug Monitoring GENERAL RELEVANCY BACKGROUND Xarelto (rivaroxaban) is an orally
Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media
News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban
Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of
Antiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
Prostate Assessment Pathway Prostate Biopsy Alerts
Prostate Assessment Pathway Prostate Biopsy Alerts Guidelines for the Management of Patient Preparation, Medications and Complications July 2015 Table of Contents Roles and Responsibilities. 1 SECTION
Are there sufficient indications for switching to new anticoagulant agents
Are there sufficient indications for switching to new anticoagulant agents Meyer Michel Samama et Gregoris Gerotziafas Groupe Hémostase-Thrombose Hôtel-Dieu, Hôpital Tenon, Paris & Biomnis Ivry/seine,
PARKINSON S DISEASE MULTIPLE DOMAINS
PhD PROGRAM IN NEUROPHARMACOLOGY UNIVERSITY OF CATANIA SUMMER SCHOOL OF NEUROSCIENCE (5) Quinta scuola estiva di Neuroscienze (5) July 7-13, 2007 PARKINSON S DISEASE MULTIPLE DOMAINS Catania Parco degli
Dec. 9, 2013, 11:00 a.m. EST
Dec. 9, 2013, 11:00 a.m. EST Portola Pharmaceuticals Announces New Phase 2 Results Confirming Immediate, Dose-Dependent and Well-Tolerated Reversal of Anticoagulation Activity of XARELTO(R) (rivaroxaban)
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,
OAC and NOAC with or without platelet inhibition
Zürich 11.06.2015 Preoperative antithrombotic management OAC and NOAC with or without platelet inhibition Miodrag Filipovic miodrag.filipovic@kssg.ch Anästhesiologie & Intensivmedizin Case 1 76 yr old
Anticoagulation before and after cardioversion; which and for how long
Anticoagulation before and after cardioversion; which and for how long Sameh Samir, MD Cardiovascular medicine dept. Tanta faculty of medicine Atrial fibrillation goals of management Identify and treat
Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia
Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia Insertion, removal or presence of a catheter in selected sites can place a patient who is antithrombotic agent at risk for a local bleeding
3/3/2015. Patrick Cobb, MD, FACP March 2015
Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict
Provided by the American Venous Forum: veinforum.org
CHAPTER 3 CLOTTING DISORDERS Original authors: Edith A. Nutescu, Jessica B. Michaud, Joseph A. Caprini, Louis W. Biegler, and Robert R. McCormick Abstracted by Kellie R. Brown Introduction The normal balance
Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
9/28/15. Dabigatran. Rivaroxaban. Apixaban. Edoxaban. From the AC Forum Centers of Excellence website: Dabigatran, Rivaroxaban, & Apixaban
Identify the FDA approved direct oral anticoagulants (DOACs) Linda Kelly, PharmD, PhC, CACP Presbyterian Healthcare Services Distinguish the differences in the dosing of DOACs for various indications Describe
DATE: 06 May 2013 CONTEXT AND POLICY ISSUES
TITLE: Low Molecular Weight Heparins versus New Oral Anticoagulants for Long-Term Thrombosis Prophylaxis and Long-Term Treatment of DVT and PE: A Review of the Clinical and Cost-Effectiveness DATE: 06
Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment
The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
Duration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences
The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences Center September 25, 2015 Question: With which of the
9/5/14. Objectives. Atrial Fibrillation (AF)
Novel Anticoagulation for Prevention of Stroke in Patients with Atrial Fibrillation Objectives 1. Review current evidence on use of warfarin in individuals with atrial fibrillation 2. Compare the three
Low Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice
Low Molecular Weight Heparin All Wales Medicines Strategy Group (AWMSG) Recommendations and advice Starting Point Low Molecular Weight Heparin (LMWH): Inhibits factor Xa and factor IIa (thrombin) Small
Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
Dabigatran and rivaroxaban, new oral anticoagulants. new approaches in dentistry
Journal section: Oral Medicine and Pathology Publication Types: Research doi:10.4317/jced.2.e1 Dabigatran and rivaroxaban, new oral anticoagulants. new approaches in dentistry Gerardo Gómez-Moreno 1, Antonio
Managing Anticoagulation for Atrial Fibrillation 2015
Managing Anticoagulation for Atrial Fibrillation 2015 Vikranth Gongidi, DO FACC FACOI Indian River Medical Center Vero Beach, FL Atrial Fibrillation Background and Guidelines Decisions to anticoagulate
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
3rd. VTE 7 (Venous Thromboembolism) most common cardiovascular condition worldwide 1. Most common avoidable cause of hospital death 2
most common cardiovascular condition worldwide 1 3rd VTE (Venous thromboembolism) Thromboembolism) 7 (Venous Thromboembolism) Most common avoidable cause of hospital death 2 EVERY Deep vein thrombosis
Anticoagulants in Atrial Fibrillation
Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives
Cardiovascular Disease
Cardiovascular Disease 1 Cardiovascular Disease 1. More target specific oral anticoagulants (TSOAC) 2. Vorapaxar (Zonivity) 3. Continued noise about a polypill 4. WATCHMAN 3 1 2 3 4 Left Atrial Appendage
Haploidentical Stem Cell Transplantation
UNIVERSITÀ DEGLI STUDI DI PARMA Preliminary Program 8 th International Symposium on Haploidentical Stem Cell Transplantation Chairman Co-Chairpersons Massimo F. Martelli, Yair Reisner Parma 4-6 September
New Anticoagulants: When and Why Should I Use Them? Disclosures
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
New Frontiers. in Glaucoma. Management. Rome, 7 February 2014 Donna Camilla Savelli Hotel
New Frontiers in Glaucoma Management Rome, 7 February 2014 Donna Camilla Savelli Hotel FACULTY Marco Centofanti University of Rome Tor Vergata Head of Glaucoma Research Line IRCCS - Fondazione Bietti Rome
New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Late-Breaking Science at ESC Congress 2015: New Real-World Evidence Reaffirms
Rx Updates New Guidelines, New Medications What You Need to Know
Rx Updates New Guidelines, New Medications What You Need to Know Maria Pruchnicki, PharmD, BCPS, BCACP, CLS Associate Professor of Clinical Pharmacy OSU College of Pharmacy Background scope and impact
American College of Allergy, Asthma & Clinical Immunology (ACAAI), USA International Center for Interdisciplinary Studies of Immunology Washington
3 rd International Symposium: New Horizons in Treatment Modalities for Allergic & Immunologic Diseases SCIENTIFIC PROGRAM October 3-4, 2008 NH Laguna Palace, Mestre Venice, Italy Organized in cooperation
Guideline for managing patients on Dabigatran (Pradaxa ) Statewide
Guideline for managing patients on Dabigatran (Pradaxa ) Statewide Custodian: Medication Safety, Medicines Regulation and Quality medicationsafety@health.qld.gov.au Developed by Medication Safety, Medicines
Clinical Guideline N/A. November 2013
State if the document is a Trust Policy/Procedure or a Clinical Guideline Clinical Guideline Document Title: Document Number 352 Version Number 1 Name and date and version number of previous document (if
Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD
Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix
Therapeutic Class Overview Oral Anticoagulants
Therapeutic Class Overview Oral Anticoagulants Therapeutic Class Overview/Summary: The oral anticoagulants, dabigatran etexilate mesylate (Pradaxa ), rivaroxaban (Xarelto ), and warfarin (Coumadin, Jantoven
Health Council of the Netherlands. New Anticoagulants: A well-dosed introduction
Health Council of the Netherlands New Anticoagulants: A well-dosed introduction Gezondheidsraad H e a l t h C o u n c i l o f t h e N e t h e r l a n d s To the Minister of Health, Welfare and Sport Subject
xaban) Policy covered: Coverage of following criteria: the following those who meet the or Hip Xarelto is For those impacted by this policy.
Xarelto (rivarox xaban) Policy Number: 5.01.575 Origination: 06/2014 Last Review: 07/2015 Next Review: 07/2016 Policy BCBSKC will provide coverage for Xarelto when it is determined to be medically necessary
SECOND CARDIOLOGY JOINT SEMINAR. Rome, April 12-13, 2012. Cardiovascular Center OLV Clinic Aalst Belgium. and
SECOND CARDIOLOGY JOINT SEMINAR Rome, April 12-13, 2012 Cardiovascular Center OLV Clinic Aalst Belgium and Cardiology Faculty of Medicine and Psychology Sapienza University, Rome, Italy Cardiology Sacred